The complete response letter, issued by the FDA, does not identify what deficiencies regulators found in ...
Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...
An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy ...
The panelist discusses, for intermediate-stage unresectable hepatocellular carcinoma (uHCC), key clinical pearls include ...
Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement of ...
Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...
Hosted on MSN29d
Immune-Onc doses first subject in trial of IO-108 for HCCThe combination therapy is intended for individuals with locally advanced, metastatic, and/or unresectable HCC. Sponsored by Roche, the trial is part of its Morpheus-Liver programme and is ...
2d
Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback